Navigation Links
Human Genome Sciences Announces Fourth Quarter and Full Year 2007 Financial Results and Recent Progress
Date:2/25/2008

and Novartis continue to expect to have the first Albuferon Phase 3 data available by late 2008, with all Phase 3 data available by spring 2009 to support the filing of global marketing authorization applications by fall 2009.

LymphoStat-B(R): Completion of Phase 3 Enrollment Expected by Fall 2008

In November 2007, Phase 2 results through 2.5 years of LymphoStat-B treatment were presented at the annual meeting of the American College of Rheumatology. Based on these results, HGS believes that LymphoStat-B (belimumab) could be a breakthrough treatment for systemic lupus erythematosus (SLE), assuming success in Phase 3. LymphoStat-B is being developed by HGS and GSK under a co-development and commercialization agreement entered into in August 2006.

Enrollment is progressing well in the pivotal Phase 3 trials of LymphoStat-B in patients with active SLE. HGS expects to complete enrollment of BLISS-76 and BLISS-52 by fall 2008, with Phase 3 data from both trials expected in 2009.

ABthrax(TM): Manufacturing on Schedule to Begin Delivery Fall 2008

HGS reported in December 2007 that it has demonstrated a statistically significant survival benefit for ABthrax (raxibacumab) in the treatment of inhalation anthrax in two animal species, which is the requirement for establishing the efficacy of new drugs used to counter bioterrorism. ABthrax is being developed under a $165 million contract with the Biomedical Advanced Research and Development Authority (BARDA) of the U.S. Department of Health and Human Services (HHS). HGS has reached agreement with the FDA on the regulatory pathway for ABthrax and plans to submit the final data package to BARDA and FDA by mid-2008 to support authorization of delivery to the Strategic National Stockpile. The Company is currently manufacturing ABthrax on schedule to begin delivery of 20,000 doses to the Stockpile by fall 2008.

Oncology Products: IAP Inhibitors Offer New Opportunities; Data from HGS- ETR1 Ph
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Expiry of Hart-Scott-Rodino Waiting Period for JUVISTA(R) (Human TGF BETA 3)
2. New Initiative Has Shocking Effect: Thousands of Missourians with Abnormal Chromosome Structures Are Not Human
3. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
4. Human Genome Sciences Announces $40 Million Milestone Payment Related to Albuferon(R) Development
5. Novocell Announces Discovery Linking Key Cancer Cell Signaling Pathways With Proliferation and Self-Renewal of Human Embryonic Stem Cells
6. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Thomas Weisel Partners Conference
7. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at BioCentury-Thomson Financial Investment Conference
8. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Bear Stearns Conference
9. Human Pheromone Sciences Enters Into Agreement to Reposition and Promote its Natural Attraction(R) Brand
10. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Merrill Lynch Conference
11. Premier Research Appoints Global Head of Human Resources
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... and NEW YORK , ... PTBI, PTBIW), a biopharmaceutical company advancing patient care in ... offering of 3,500,000 shares of common stock, and warrants ... common stock, at an offering price of $4.00 per ... per share exercise price of $5.00, are exercisable immediately, ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 Earlier this ... James L. Sherley, director of the Adult Stem Cell ... an often overlooked and under appreciated unique property of ... by Distributed Stem Cells: Misunderstood in the Past, Important ... to congress participants. He gave the address at ...
(Date:12/24/2014)... Nashville, Tenn. (PRWEB) December 23, 2014 ... Hill was elected treasurer for the American Society ... to advancing knowledge and research in reproductive medicine. ... fills a seat on the executive board and will ... , Dr. Hill has actively supported ASRM since ...
(Date:12/24/2014)... December 23, 2014 PharmaBoardroom,s ... out today and available for free download , digs ... change and growth in the sector today. One ... successes has been in developing a homegrown pharmaceutical manufacturing base, ... production still remains some way off. A cursory comparison with ...
Breaking Biology Technology:PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 3PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3
... Mass., March 31 Boston Scientific,Corporation (NYSE: ... Scientific Santa,Rosa Corp., formerly known as TriVascular, Inc., ... in Santa Rosa, California. Boston Scientific,Santa Rosa Corp. ... endovascular aortic repair (EVAR) program. Terms of the ...
... ... Year-over-Year, ALISO VIEJO, Calif., ... and services resource for,pathologists, oncologists and the pharmaceutical industry, today announced,financial ... from continuing operations was $12.4 million for the fourth quarter,of 2007, ...
... poster ... presentations, SOUTH SAN FRANCISCO, Calif., March ... clinical,trials of the company,s investigational compounds XL647, XL184, XL765 and,XL880 will be ... will be held from May 30 to June 3, 2008 in,Chicago, Illinois. ...
Cached Biology Technology:Boston Scientific Announces Sale of TriVascular Endovascular Aortic Repair Program 2Boston Scientific Announces Sale of TriVascular Endovascular Aortic Repair Program 3Clarient Announces Fourth Quarter and Year-End 2007 Financial Results 2Clarient Announces Fourth Quarter and Year-End 2007 Financial Results 3Clarient Announces Fourth Quarter and Year-End 2007 Financial Results 4Clarient Announces Fourth Quarter and Year-End 2007 Financial Results 5Clarient Announces Fourth Quarter and Year-End 2007 Financial Results 6Clarient Announces Fourth Quarter and Year-End 2007 Financial Results 7Clarient Announces Fourth Quarter and Year-End 2007 Financial Results 8Clarient Announces Fourth Quarter and Year-End 2007 Financial Results 9Seven Abstracts Featuring Exelixis Compounds Accepted for Presentation at 2008 ASCO Annual Meeting 2
(Date:12/17/2014)... 15, 2014  HITLAB SM announced today ... audit to confirm its adherence to current U.S. ... enables HITLAB to conduct regulated smart device and ... for patient safety and research quality. ... quality, and delivery with innovative technology," said ...
(Date:12/17/2014)... DUBLIN , Dec. 16, 2014 Research ... announced the addition of the "Global Chemical ... http://photos.prnewswire.com/prnh/20130307/600769 ... is the increasing demand for medical sensors in ... patient data for quick and correct diagnosis during ...
(Date:12/15/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/87pph8/global_facial ) ... Facial Recognition Market 2015-2019" report to their ... Facial recognition is a technology used ... measures the overall facial feature of a person ... distance between eyes. Facial recognition is used for ...
Breaking Biology News(10 mins):HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... RIVERSIDE, Calif. Julia Bailey-Serres , a geneticist whose ... will give a free, public lecture at UC Riverside on ... challenge of improving crop yield in the face of climate ... Solutions," the hour-long lecture will begin at 7 p.m. in ...
... This press release is available in Spanish . ... calves has been developed by Agricultural Research Service (ARS) scientists who ... nutrient the young animals need to promote optimal growth and health. ... from their mothers as they nurse during the first few days ...
... discovered a defect in cellular pathways that provides a new ... newborns, known as craniosynostosis. Mutations of the WNT ... that regulate bone formation at the stem cell level, according ... Science Signaling . "Our work contributes to the ...
Cached Biology News:Public lecture to explore solutions to the food challenge 2Public lecture to explore solutions to the food challenge 3Model developed for manipulating vitamin D levels in calves 2Stem-cell disruption induces skull deformity, UR study shows 2
Mouse monoclonal [RL13] to LAP1 ( Abpromise for all tested applications). SwissProtID: Q96NW7...
CircuLex Anti-Human S100P Polyclonal Antibody Research Focus: proliferation Storage: -20C Shipping Temperature: 4C...
Mouse monoclonal [7E10] to C Peptide ( Abpromise for all tested applications). entrezGeneID: 3630 SwissProtID: P01308...
Dual adapter for phosphotyrosine and 3-phosphotyrosine and 3-phosphoinositide...
Biology Products: